PR Newswire | Sep 11, 2020 07:31AM EDT

09/11 06:30 CDT

Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences MARINA DEL REY, Calif., Sept. 11, 2020

MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.

Presentation details:

Event: HC Wainwright Virtual 22nd Annual Global Investment ConferenceDate: Tuesday, September 15, 2020Time: 3:00-3:20pm EDT

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Tuesday, September 22, 2020Time: 4:10-4:50pm EDT

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Media Contacts:

At Armata:Steve MartinArmata Pharmaceuticals, Inc.ir@armatapharma.com858-800-2492

Armata Investor Relations:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com212-915-2569

View original content to download multimedia: http://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-301128034.html

SOURCE Armata Pharmaceuticals, Inc.